Telomir Pharmaceuticals (TELO) Financials

Telomir Pharmaceuticals (NASDAQ: TELO) remains in a very early-stage, pre-revenue position, and the latest quarter shows the company still burning cash while relying on external financing to keep operations funded. Over the last several years, the biggest trend is not sales growth, but a rapidly changing cash position, recurring losses, and repeated equity/debt issuance to support operations.

For retail investors, the key takeaway is straightforward: TELO is still a development-stage biotech with no revenue, meaningful quarterly losses, and a balance sheet that can swing sharply depending on financing activity. That said, the company ended Q1 2026 with a much stronger cash balance than it had a year earlier, which gives it more near-term flexibility.

• Cash increased materially year over year: cash and equivalents rose to $5.6 million in Q1 2026 from $0.4 million in Q1 2025, giving the company a larger liquidity cushion.
• Equity improved from a deficit to positive equity: total common equity improved to $5.0 million in Q1 2026 from a negative $0.2 million in Q1 2025, reflecting a much healthier balance sheet than a year ago.
• Leverage remains modest: total liabilities were only $827,310 in Q1 2026, which is low relative to cash and total assets.
• Operating cash burn improved versus late 2025: operating cash outflow was $1.77 million in Q1 2026, better than the $2.06 million net loss in Q4 2025 and well below some earlier periods.
• Raising capital is still supporting the business: Q3 2025 saw large financing inflows from debt and common equity issuance, which helped boost cash substantially.
• No revenue has been reported: the company reported $0 in revenue in every quarter provided, so performance is entirely dependent on pipeline progress and financing.
• Interest income is helping a little: TELO has generated some non-operating income from cash/investments, but it is far too small to offset operating losses.
• Share count has increased over time: the weighted average share count has generally trended higher, which suggests dilution has been part of funding operations.
• Losses remain substantial: Q1 2026 net loss was $991K, after a $2.06 million loss in Q4 2025 and an even larger $5.07 million loss in Q2 2025.
• Operating cash flow is consistently negative: the company has not generated positive operating cash flow in the periods provided, with Q1 2026 still showing a $1.77 million outflow.

Looking at the broader trend, TELO’s quarterly losses have generally been large and inconsistent, while operating expenses have fluctuated widely. For example, Q2 2025 was especially expensive, with operating expenses above $5.0 million, while Q1 2026 operating expenses dropped to about $1.0 million. That kind of volatility is common for clinical-stage biotech companies, but it also makes forecasting difficult.

The balance sheet shows a major improvement in liquidity compared with early 2025. Cash rose from $403K in Q1 2025 to $5.6 million in Q1 2026, and total equity moved sharply higher. However, that improvement appears tied in part to financing activity rather than self-sustaining operations, which means dilution risk remains an important factor for shareholders.

Bottom line: Telomir Pharmaceuticals is in a funding-and-development phase, not a revenue-generating phase. The company’s improved cash position is encouraging, but persistent losses, negative operating cash flow, and reliance on financing make the stock highly speculative.